Clinical trials: Hope Level
Spinal Cord Injury at C5-C7 Level
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI
This study is expanded access to an Investigational New Drug (IND) for an individual patient with spinal cord injury (SCI) at cervical spine 5-6 (C 5-6) designed to provide access to autologous adipose-derived mesenchymal stem…
- Trial name
- NCT03925649
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences LLC